Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

e sample sizes were too small to draw firm conclusions.

About the SPIRIT III Trial

SPIRIT III is a prospective, multi-center, randomized, single-blind, controlled clinical trial comparing XIENCE V to TAXUS in 1,002 patients (669 XIENCE V patients, 333 TAXUS patients) with either one or two de novo coronary artery lesions. The trial was conducted across 65 academic and community-based centers in the United States between June 22, 2005, and March 15, 2006.

The primary endpoint of the SPIRIT III trial was in-segment late loss at eight months, wherein XIENCE V demonstrated superiority to TAXUS with a statistically superior 50 percent reduction in late loss (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS, p-value =0.004). In-segment late loss is a measure of vessel re-narrowing.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION((R)) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

Abbott's market-leading XIENCE V drug eluting stent is commercially available in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmace
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Unique ... Groups Inc.: OTC Pink: UPZS), a Delaware Corporation, ... distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based ... According to the agreement, US-based Larasan will work ... 6" frozen pizza through Larasan,s vast distribution network ...
(Date:7/30/2014)... 2014 Silicon Valley Bank, the bank of ... that examines the merger, acquisition and IPO activity ... to the annual report based on 2013 data, venture ... SVB started tracking the data in 2005. ... solid healthcare M&A activity over the last few years, ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... Fourth - Quarter 2010 Highlights ... Gross profit increased by 5.8% over Q4 FY09 to $8.8 ... $3.1 million with EPS of $0.13 Full Fiscal ... $115.0 million Gross Profit increased 23.7% YOY to $34.6 million ...
... Otonomy, Inc . announced today that David A. Weber, ... of the Board of Directors. Jay Lichter, Ph.D., managing director of ... continue to actively support the company as a member of the ... Dr. Weber to the Otonomy team, as his extensive experience in ...
Cached Medicine Technology:Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 2Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 3Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 4Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 5Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 6Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 7Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 8Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 9Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 10Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 11Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 12Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 13Winner Medical Reports Fourth Quarter and Fiscal 2010 Results 14Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3
(Date:7/30/2014)... to artemisinin, the main drug to treat malaria, ... Plasmodium falciparum ( P. falciparum ) ... caused by a genetic mutation in the parasites. ... opposed to a standard three-day coursehas proved highly ... findings published today in the New England ...
(Date:7/30/2014)... Steven Reinberg HealthDay Reporter ... the United States, at least 2,000 Americans die from extreme ... Heat waves, heat stroke or sun stroke caused nearly ... and 2010, according to the U.S. Centers for Disease Control ... loss of body heat -- accounted for 63 percent of ...
(Date:7/30/2014)... News) -- It can happen in an instant: A small ... monitor and gets critically injured when the furniture tips over. ... look around their homes and imagine what could tip over, ... better than it becoming a reality," Dr. Alex Rosenau, president ... college news release. Between 2009 and 2011, roughly 43,000 ...
(Date:7/30/2014)... Hayward, CA (PRWEB) July 30, 2014 ... and accessories at the lowest prices on the internet ... Lightning Cables in two lengths and two colors. These ... performance standards. , The high quality SF Cable ... 8-pin connector with digital signal delivering faster charging and ...
(Date:7/30/2014)... York (PRWEB) July 30, 2014 The ... brain bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... blood thinner, Bernstein Liebhard LLP reports. According to the ... the District of Vermont on July 25th, the decedent ... he suffered an irreversible brain bleed that ultimately led ...
Breaking Medicine News(10 mins):Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:Tip-Over Furniture Can Kill Kids 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3
... News) -- More than half of U.S. jails didn,t receive ... H1N1 swine flu, a new study says. Jail and ... diseases. The steady stream of new arrivals can introduce new ... it easy for diseases to spread, researchers from the U.S. ...
... have been linked to depression, according to UT Southwestern ... Study. It is believed to be the largest such ... already are associated with a cavalcade of health woes ... published in Mayo Clinic Proceedings ...
... , THURSDAY, Jan. 5 (HealthDay News) -- Toddlers who miss ... later in life, a new study indicates. Researchers looked ... that depriving them of a single daily nap resulted in ... problem-solving abilities. "Many young children today are not getting ...
... clinical trial found that rilonacept, an inhibitor of ... flares that occur when initiating uric acid-lowering therapy. ... IL-1 targeted therapy in prevention of gout flaresshow ... serious infections or treatment-related serious adverse events reported. ...
... vector-borne disease in the United States, with the majority of ... since the agent of the disease, the spirochete Borrelia ... However, the number of Lyme disease cases have steadily increased. ... of the Journal of Medical Entomology called "What ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- A vaccine ... severe liver damage and even liver cancer, might be possible ... , There is currently no vaccine for hepatitis C, which ... HIV, the hepatitis C virus mutates easily and has always ...
Cached Medicine News:Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Low vitamin D levels linked to depression, UT Southwestern psychiatrists report 2Health News:Missed Naps Could Put Toddlers at Risk for Mood Disorders 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 3Health News:How can Lyme disease be prevented and controlled? 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3
Molteno3 Glaucoma Drainage Device incorporates the latest advances from Professor Moltenos glaucoma research. It has been extensively tested since early 2004 and gives even better control of intraocu...
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
Medicine Products: